69
References
- Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W et al (2014) Blockade of oncogenic
IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal
domain protein inhibitors. Proc Natl Acad Sci U S A 111:11365–11370 - Morini E, Dietrich P, Salani M, Downs HM, Wojtkiewicz GR et al (2016) Sensory and auto-
nomic deficits in a new humanized mouse model of familial dysautonomia. Hum Mol Genet
25:1116–1128 - Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured Lymphoblasts from
Burkitt’s lymphoma. Lancet 1:702–703 - Lu F, Wikramasinghe P, Norseen J, Tsai K, Wang P et al (2010) Genome-wide analysis of
host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1). Virol
J 7:262 - Henle G, Henle W, Diehl V (1968) Relation of Burkitt’s tumor-associated herpes-ytpe virus
to infectious mononucleosis. Proc Natl Acad Sci U S A 59:94–101 - Pope JH (1967) Establishment of cell lines from peripheral leucocytes in infectious mono-
nucleosis. Nature 216:810–811 - Henle W, Diehl V, Kohn G, Zur Hausen H, Henle G (1967) Herpes-type virus and chro-
mosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science
157:1064–1065 - Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L et al (2011) Inhibition of ana-
plastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-
positive human diffuse large B cell lymphomas. PLoS One 6:e18436 - Mesri EA, Feitelson MA, Munger K (2014) Human viral oncogenesis: a cancer hallmarks
analysis. Cell Host Microbe 15:266–282 - Rund D (2014) Targeting drug resistance to close the gap in diffuse large B-cell lymphoma.
Leuk Lymphoma 55:1966–1967 - Lv X, Feng L, Ge X, Lu K, Wang X (2016) Interleukin-9 promotes cell survival and drug
resistance in diffuse large B-cell lymphoma. J Exp Clin Cancer Res 35:106 - Yang C, Lu P, Lee FY, Chadburn A, Barrientos JC et al (2008) Tyrosine kinase inhibition in
diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of
dasatinib. Leukemia 22:1755–1766 - Wilson WH (2006) Drug resistance in diffuse large B-cell lymphoma. Semin Hematol
43:230–239 - Yu X, Li Z (2015) New insights into MicroRNAs involves in drug resistance in diffuse large
B cell lymphoma. Am J Transl Res 7:2536–2542 - Parker GA, Touitou R, Allday MJ (2000) Epstein-Barr virus EBNA3C can disrupt multiple
cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene
19:700–709 - Banerjee S, Lu J, Cai Q, Saha A, Jha HC et al (2013) The EBV latent antigen 3C inhibits
apoptosis through targeted regulation of interferon regulatory factors 4 and 8. PLoS Pathog
9:e1003314 - Tsimbouri P, Drotar ME, Coy JL, Wilson JB (2002) bcl-xL and RAG genes are induced and
the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene
21:5182–5187 - De Paepe P, De Wolf-Peeters C (2007) Diffuse large B-cell lymphoma: a heterogeneous
group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities.
Leukemia 21:37–43 - Rosenwald A, Wright G, Chan WC, Connors JM, Campo E et al (2002) The use of molecular
profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl
J Med 346:1937–1947 - Heslop HE (2005) Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lym-
phomas. Hematol Am Soc Hematol Educ Program: 260–266
5 EBV-Associated B-Cell Lymphomas